NDA 215830 · Pfizer
Litfulo
Ritlecitinib Tosylate · Oral
NovelCDER novel approval, Jun 23, 2023: To treat severely patchy hair loss
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 23, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
9 Phase 3, 8 recruiting
FAERS reports
1,963
398 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death, including tuberculosis (TB). Interrupt treatment if serious infection occurs until the infection is controlled. LITFULO should not be given to patients with active tuberculosis. Test for latent TB before and during therapy; start treating latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ). Monitor all patients for signs and symptoms of infection during and after treatment with LITFULO. ( 5.1 ) •...
What it is approved for
From the label in effect Jun 17, 2026.
LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. ( 1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants ( 1 ).
Mechanism: LITFULO is a kinase inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated by JAK3-dependent receptors. Additionally, ritlecitinib inhibits signaling of immune receptors dependent on TEC kinase family members. The relevance of inhibition of specific JAK or TEC family enzymes to therapeutic effectiveness is not currently known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LITFULO · RITLECITINIB TOSYLATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ritlecitinib" as an intervention, any sponsor and status, largest first.
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06072183 · 1,571 participants · Start Nov 8, 2023 · Primary completion Jul 30, 2027
Drug: Ritlecitinib; Ritlecitinib and 1 more · For: Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo
Sites: Scottsdale, Arizona; Bryant, Arkansas; Fountain Valley, California · 229 sites in all
- Long-Term PF-06651600 for the Treatment of Alopecia AreataPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04006457 · 1,057 participants · Start Jul 18, 2019 · Primary completion Jun 25, 2024
Drug: PF-06651600; Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine and 1 more · For: Alopecia Areata
Sites: Birmingham, Alabama; Beverly Hills, California; Irvine, California · 144 sites in all
- PF-06651600 for the Treatment of Alopecia AreataPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03732807 · 718 participants · Start Dec 3, 2018 · Primary completion Dec 31, 2020
Drug: PF-06651600 Induction Dose; PF-06651600 Maintenance Dose #1 and 3 more · For: Alopecia Areata
Sites: Birmingham, Alabama; Beverly Hills, California; Irvine, California · 155 sites in all
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06873945 · 674 participants (planned) · Start Apr 1, 2025 · Primary completion Mar 19, 2028
Drug: Ritlecitinib 100 mg; Ritlecitinib 50 mg and 2 more · For: Alopecia Areata
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Brea, California · 148 sites in all
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05583526 · 607 participants · Start Dec 1, 2022 · Primary completion Feb 5, 2026
Drug: Ritlecitinib; Placebo · For: Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo
Sites: Birmingham, Alabama; Encinitas, California; Huntington Beach, California · 115 sites in all
- TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATEPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04413617 · 460 participants · Start Jul 29, 2020 · Primary completion Feb 7, 2022
Drug: PF-06650833; PF-06651600 and 1 more · For: Rheumatoid Arthritis
Sites: Pleven, Bulgaria; Plovdiv, Bulgaria; Rousse, Bulgaria · 144 sites in all
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06163326 · 394 participants · Start Jan 19, 2024 · Primary completion Mar 31, 2027
Drug: Ritlecitinib; Ritlecitinib 100 mg and 1 more · For: Vitiligo
Sites: Encinitas, California; Huntington Beach, California; Los Angeles, California · 73 sites in all
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07733765 · 336 participants (planned) · Start Jul 30, 2026 · Primary completion Apr 26, 2028
Drug: Ritlecitinib 100 mg; Ritlecitinib 50 mg · For: Alopecia Areata
Sites: Encinitas, California; Miami, Florida; Skokie, Illinois · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective346
- therapeutic product effect incomplete135
- condition aggravated120
- off label use109
- headache91
- alopecia66
- diarrhoea66
- urticaria55
- product dose omission issue51
- pruritus50
- fatigue45
- acne44
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 156 |
| 2024 | 722 |
| 2025 | 771 |
| 2026 | 311 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Litfulo (Ritlecitinib Tosylate)
2024 spending
$5.1M
Beneficiaries
274
1,155 claims
Per beneficiary
$18,720
$139.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $223,742 |
| 2024 | $5,129,379 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.
Tziotzios C, Sinclair R, Lesiak A, et al. · J Eur Acad Dermatol Venereol 2025 · Clinical Trial, Phase III, Multicenter Study
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.
Aceituno D, Fawsitt CG, Power GM, et al. · J Eur Acad Dermatol Venereol 2025 · Comparative Study, Systematic Review
- Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, et al. · J Am Acad Dermatol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.
Guttman-Yassky E, Del Duca E, Da Rosa JC, et al. · J Allergy Clin Immunol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B, Soung J, Tziotzios C, et al. · Am J Clin Dermatol 2024 · Clinical Trial, Video-Audio Media
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.